Internal Medicine, Hematology & Oncology · Mountain Lakes, NJ
NPI
1750502811
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
333 Route 46 W
Mountain Lakes, NJ, 07046
Phone (973) 316-1701
Groups this clinician bills Medicare through
Medicare paid, 2024
$143K
26,082 services
Medicare patients, 2024
174
Average age 74
Drug cost, 2024
$2.7M
733 prescriptions
Company payments, 2025
$1,413
From 32 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ruby Hanna was code J1439 (injection, ferric carboxymaltose, 1 mg), 20,250 times for 17 patients. In total Ruby Hanna billed 26,082 services in 59 codes, and Medicare paid $143K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-06-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 20,250 | 17 | $0.87 | $18K |
| 85025 Blood Count | Office | 337 | 143 | $7.55 | $2,545 |
| 99214 Office E&M - Established | Office | 312 | 133 | $99.91 | $31K |
| 36415 Venipuncture Blood Collection | Office | 274 | 131 | $8.65 | $2,370 |
| 96372 Injection Administration | Office | 104 | 24 | $11.44 | $1,190 |
| 99213 Office E&M - Established | Office | 60 | 48 | $66.87 | $4,012 |
| 96375 Injection Administration | Office | 55 | 12 | $13.05 | $718 |
| 99204 Office E&M - New | Office | 43 | 43 | $130.05 | $5,592 |
| 96413 Chemotherapy Administration | Office | 42 | 14 | $111.29 | $4,674 |
| 80048 Clinical Chemistry | Office | 32 | 16 | $8.07 | $258 |
| 96365 Intravenous Infusion, Hydration | Office | 27 | 18 | $53.68 | $1,449 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 16 | 16 | $13.57 | $217 |
By year: 2022 $281K for 35,089 services; 2023 $193K for 21,202 services; 2024 $143K for 26,082 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 337 | 143 | $7.55 | $2,545 |
| 36415 Venipuncture Blood Collection | 274 | 131 | $8.65 | $2,370 |
| 80048 Clinical Chemistry | 32 | 16 | $8.07 | $258 |
Medicare prescription drug claims, 2024
In 2024, the drug Ruby Hanna prescribed most often to Medicare patients was Anastrozole, with 58 prescriptions and refills. In total Ruby Hanna wrote 733 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 58 | 130 | 16 | $1,249 |
| Ibrance Palbociclib | 53 | 53 | Under 11 | $816K |
| Hydroxyurea Generic | 42 | 85 | Under 11 | $835 |
| Palonosetron Hcl Generic | 39 | 39 | Under 11 | $1,756 |
| Ondansetron Hcl Generic | 35 | 35 | 15 | $111 |
| Procrit Epoetin Alfa | 32 | 32 | 18 | $123K |
| Fulvestrant Generic | 31 | 31 | Under 11 | $31K |
| Carboplatin Generic | 30 | 30 | Under 11 | $1,425 |
| Fosaprepitant Dimeglumine Generic | 27 | 27 | Under 11 | $6,595 |
| Keytruda Pembrolizumab | 24 | 25 | Under 11 | $302K |
| Paclitaxel Generic | 23 | 23 | Under 11 | $1,565 |
| Imbruvica Ibrutinib | 21 | 21 | Under 11 | $334K |
| Granisetron Hcl Granisetron Hcl/Pf | 21 | 21 | Under 11 | $359 |
| Udenyca Autoinjector Pegfilgrastim-Cbqv | 18 | 18 | Under 11 | $74K |
| Zirabev Bevacizumab-Bvzr | 18 | 18 | Under 11 | $73K |
Brand drugs: 315 claims; generic drugs: 418 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ruby Hanna $1,413 ($1,413 in general payments such as food, travel and fees) from 32 companies. The largest payer was Daiichi Sankyo Inc. with $141.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 7 | $141 |
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $119 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $117 |
| Karyopharm Therapeutics Inc. KPTI | 3 | $101 |
| GlaxoSmithKline, LLC. GSK | 5 | $97.52 |
| Merck Sharp & Dohme LLC MRK | 4 | $79.79 |
| Celgene Corporation BMY | 4 | $68.34 |
| Genmab U.S., Inc. GMAB | 3 | $61.78 |
| Geron Corporation GERN | 3 | $50.73 |
| Incyte Corporation INCY | 3 | $49.29 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.